A new study published in The Lancet reported that Boehringer Ingelheim’s BI 695501 (biosimilar adalimumab) has similar safety and efficacy to reference adalimumab in patients with Crohn’s disease.
Print Page Mail ArticleSchlam dunk – Federal Court makes Norwich Pharmacal orders against third party new employer
Following a trend of cases being filed by employers against ex-employees in the Federal Court for breach of confidence and copyright infringement,...